Zhejiang Orient Gene Biotech Co., Ltd
Shanghai Stock ExchangeTotal Valuation
Zhejiang Orient Gene Biotech Co., Ltd carries a market capitalization of 3.82B, placing it among publicly traded companies globally. Its enterprise value stands at 3.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.82B |
| Enterprise Value | 3.19B |
Share Statistics
Zhejiang Orient Gene Biotech Co., Ltd currently has 201.60M shares outstanding.
| Shares Outstanding | 201.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 6.82, and the price-to-book ratio stands at 0.89.
| PE Ratio | N/A |
| PS Ratio | 6.82 |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | 7.41 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 3.92 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 4.19 |
Financial Position
Zhejiang Orient Gene Biotech Co., Ltd maintains a current ratio of 4.21, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.99, indicating elevated leverage, while an interest coverage ratio of -41.25 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.21 |
| Quick Ratio | 3.40 |
| Debt / Equity | 4.99 |
| Debt / EBITDA | -0.55 |
| Interest Coverage | -41.25 |
Financial Efficiency
| Return on Equity (ROE) | -8.33 |
| Return on Assets (ROA) | -6.73 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.48 |
Taxes
| Income Tax | -18.13M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Zhejiang Orient Gene Biotech Co., Ltd's stock has declined approximately -29.35917% over the past 52 weeks. The 50-day moving average sits at 21.06, while the 200-day moving average is 23.73.
| Beta (5Y) | N/A |
| 52-Week Price Change | -29.35917% |
| 50-Day Moving Average | 21.06 |
| 200-Day Moving Average | 23.73 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Zhejiang Orient Gene Biotech Co., Ltd generated 812.76M in revenue and converted that into -540.51M in net income, yielding earnings per share of -2.88. EBITDA reached -595.47M, while operating income came in at -595.47M.
| Revenue | 812.76M |
| Gross Profit | 265.49M |
| Operating Income | -595.47M |
| Pretax Income | -600.97M |
| Net Income | -540.51M |
| EBITDA | -595.47M |
| EBIT | -595.47M |
| Earnings Per Share (EPS) | -2.88 |
Balance Sheet
Zhejiang Orient Gene Biotech Co., Ltd holds 2.82B in cash and equivalents against 329.16M in total debt, resulting in a net debt position of -2.22B. Total book value stands at 6.22B, with working capital of 2.66B providing operational flexibility.
| Cash & Cash Equivalents | 2.82B |
| Total Debt | 329.16M |
| Net Debt | -2.22B |
| Equity (Book Value) | 6.22B |
| Book Value Per Share | 30.72 |
| Working Capital | 2.66B |
Cash Flow
After subtracting -747.89M in capital expenditures, free cash flow totaled -747.89M - equivalent to -3.69 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -747.89M |
| Free Cash Flow | -747.89M |
| FCF Per Share | -3.69 |
Margins
Zhejiang Orient Gene Biotech Co., Ltd operates with a gross margin of 32.66, reflecting its pricing power and cost economics. The operating margin of -73.27 and net profit margin of -66.50 provide insight into operational efficiency.
| Gross Margin | 32.66 |
| Operating Margin | -73.27 |
| Pretax Margin | -73.94 |
| Profit Margin | -66.50 |
| EBITDA Margin | -73.27 |
Dividends & Yields
The company's payout ratio of -2.05 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.06 |
| Dividend Yield | N/A |
| Payout Ratio | -2.05 |
| Shareholder Yield | 5.27 |
| FCF Yield | 13.50 |
Stock Splits
Zhejiang Orient Gene Biotech Co., Ltd's most recent stock split took place on June 26, 2023 with a 5:6 split ratio.
| Last Split Date | 6/26/2023 |
| Split Ratio | 5:6 |
Scores
Zhejiang Orient Gene Biotech Co., Ltd posts an Altman Z-Score of 4.79, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.79 |